Non-BCMA-Targeting Bispecifics in the Treatment of R/R Multiple Myeloma

home / case-based-peer-perspectives / non-bcma-targeting-bispecifics-in-the-treatment-of-r-r-multiple-myeloma

Peter Voorhees, MD, presents the case of a 63-year-old man with R/R multiple myeloma and discusses the potential role of non-BCMA-targeting bispecifics in the treatment landscape for multiple myeloma.

$Case Presentation: A 63-Year-Old Patient with Relapsed-Refractory (R/R) Multiple Myeloma$

EP. 1: Case Presentation: A 63-Year-Old Patient with Relapsed-Refractory (R/R) Multiple Myeloma

Peter Voorhees, MD

January 25th 2023

Peter Voorhees, MD, presents a case of a 63-year-old man with R/R multiple myeloma, shares his initial impressions, and discusses the assessment of clinical relapse in patients with R/R multiple myeloma.

Watch

EP. 2: MonumenTAL-1 and Bispecifics Under Development for The Treatment of R/R Multiple Myeloma

Peter Voorhees, MD

January 25th 2023

Dr Peter Voorhees reviews bispecifics under development and updated outcomes data from the MonumenTAL-1 trial, evaluating talquetamab in patients with R/R multiple myeloma.

Watch

EP. 3: MoumenTAL-1: Management of Adverse Events and Health-Related Quality of Life Outcomes

Peter Voorhees, MD

January 25th 2023

Dr Peter Voorhees highlights MonumenTAL-1, discussing management of notable adverse events and health-related quality of life outcomes from patients with R/R multiple myeloma.

Watch

EP. 4: Comparing Bispecifics, ADCs, and CAR T-Cell Therapy for the Treatment of MM

Peter Voorhees, MD

January 25th 2023

Dr Voorhees shares his perspective on bispecifics, ADCs, and CAR T-cell therapy in the treatment landscapes of R/R multiple myeloma.

Watch

EP. 5: Advice to Community Oncologists Treating with Bispecifics

Peter Voorhees, MD

January 25th 2023

Dr Peter Voorhees outlines advice for community oncologists who treat patients with R/R multiple myeloma.

Watch

About Us